FDA panel recommends Luxturna gene therapy – AOP
BioPharma-Reporter.com |
FDA panel recommends Luxturna gene therapy
AOP Diopsys advert A gene therapy for the treatment of the inherited eye disease, Leber congenital amaurosis (LCA), is a step closer to approval by the US Food and Drug Administration (FDA). The FDA's Cellular, Tissue and Gene Therapies Advisory Committee … 'Luxturna' recommendation good for all AAV based gene therapies says advocacy group |
